Suven Pharmaceuticals Limited has officially rebranded as Cohance Lifesciences Limited, signaling a strategic transformation into a specialized, technology-driven global CDMO (Contract Development and Manufacturing Organization). The rebranding reflects the company’s renewed focus on partnering with global innovators to enhance therapeutics and deliver transformative solutions worldwide.
Executive Chairman Mr. Vivek Sharma stated that the transition represents a pivotal step in building a future-ready CDMO platform, capable of supporting diverse chemistries, technologies, and therapeutic modalities.
The Ministry of Corporate Affairs (MCA), Government of India, approved the name change effective May 7, 2025, following a Scheme of Amalgamation. The company will now apply to BSE and NSE for the formal update, and the new name has been incorporated into its Memorandum and Articles of Association.